Przejdź do zawartości
Merck

A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity.

Nature communications (2020-02-15)
Louisa Nelson, Anthony Tighe, Anya Golder, Samantha Littler, Bjorn Bakker, Daniela Moralli, Syed Murtuza Baker, Ian J Donaldson, Diana C J Spierings, René Wardenaar, Bethanie Neale, George J Burghel, Brett Winter-Roach, Richard Edmondson, Andrew R Clamp, Gordon C Jayson, Sudha Desai, Catherine M Green, Andy Hayes, Floris Foijer, Robert D Morgan, Stephen S Taylor
ABSTRAKT

High-grade serous ovarian carcinoma is characterised by TP53 mutation and extensive chromosome instability (CIN). Because our understanding of CIN mechanisms is based largely on analysing established cell lines, we developed a workflow for generating ex vivo cultures from patient biopsies to provide models that support interrogation of CIN mechanisms in cells not extensively cultured in vitro. Here, we describe a "living biobank" of ovarian cancer models with extensive replicative capacity, derived from both ascites and solid biopsies. Fifteen models are characterised by p53 profiling, exome sequencing and transcriptomics, and karyotyped using single-cell whole-genome sequencing. Time-lapse microscopy reveals catastrophic and highly heterogeneous mitoses, suggesting that analysis of established cell lines probably underestimates mitotic dysfunction in advanced human cancers. Drug profiling reveals cisplatin sensitivities consistent with patient responses, demonstrating that this workflow has potential to generate personalized avatars with advantages over current pre-clinical models and the potential to guide clinical decision making.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
Retinoic acid, ≥98% (HPLC), powder
Sigma-Aldrich
Nutlin-3, ≥98% (HPLC), powder
Sigma-Aldrich
Przeciwciało anty-fosfo-histonowe H3 (Ser10), marker mitozy, Upstate®, from rabbit
Sigma-Aldrich
Anti-CD44 Rat mAb (A020), liquid, clone A020, Calbiochem®